Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-882-0 | CAS number: 34206-40-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: Key study: Test according to OECD guideline 401. GLP study. LD50 was determined to be 2317.10 mg/kg bw.
Acute dermal toxicity: Key study: Test method according to OECD 402. GLP study. LD50 was determined to be > 2000 mg/kg bw.
Acute inhalation toxicity: Data waiving (other justification): According to REACH Annex VIII, column 2, the study was not needed to be performed since the choice for the second routh in addition for the oral route was provided for dermal route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
The analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime which shares the same functional group with butan-2-one O,O',O'',O'''-silanetetrayltetraoxime, also has comparable values for the relevant molecular properties for acute toxicity.
See attached reporting format. - Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 282.81 mg/kg bw
- Based on:
- test mat.
- Remarks:
- (analogue substance)
- Remarks on result:
- other: (Method of Bliss) (Based on read-across approach from an anaogue)
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 273.54 mg/kg bw
- Based on:
- test mat.
- Remarks:
- (analogue substance)
- Remarks on result:
- other: (Method of Litchfield & Wilcoxon) (Based on read-across approach from an anlogue)
- Interpretation of results:
- not classified
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- Based on the read-across approach from experimental results on analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime, the oral LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was determined to be 2282.81 mg/kg bw in rats.
- Executive summary:
An acute study was perfomed in accordance with OECD 401 and GLP on the analogue substance butan-2-one O,O',O''-(methylsilylidyne)trioxime. The LD50 was determined to be 2463 mg/kg bw. Based on these results the read-across was applied and the oral LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was determined to be 2282.81 mg/kg bw in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 282.81 mg/kg bw
- Quality of whole database:
- The key study is a GLP compliant and has Klimisch score 1. The quality of the database was determined as appropriate for assessment.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
The analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime which shares the same functional group with butan-2-one O,O',O'',O'''-silanetetrayltetraoxime, also has comparable values for the relevant molecular properties for acute toxicity.
See attached reporting format. - Reason / purpose for cross-reference:
- read-across source
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000
- Based on:
- test mat.
- Remarks:
- (analogue substance)
- Remarks on result:
- other: (based on read-across approach from an analogue)
- Interpretation of results:
- not classified
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- Based on the read-across approach from experimental results on analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime, the dermal LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was determined to be >2000 mg/kg bw in rats.
- Executive summary:
An acute dermal toxicity test was perfomed in accordance with OECD 402 and GLP on analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime in rats. No effects were observed and the dermal LD50 was determined to be >2000 mg/kg bw. Based on these results, the read-across was applied and the dermal LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was also determined to be >2000 mg/kg bw in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 2 000 mg/kg bw
- Quality of whole database:
- The study is a GLP compliant and has Klimisch score 1. The quality of the database was determined as appropriate for assessment.
Additional information
Acute oral toxicity: Read-across from experimental data on analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime:
Key study: An acute study was perfomed in accordance with OECD 401 and GLP on the analogue substance butan-2-one O,O',O''-(methylsilylidyne)trioxime were the LD50 was determined to be 2463 mg/kg bw. Based on these results the read-across was applied and the oral LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was determined to be 2282.81 mg/kg bw in rats.
Supporting study: An acute oral study was performed with a method similar to OECD Guideline 401 and GLP on the analogue substance butan-2-one O,O',O''-(methylsilylidyne)trioxime in rats. The oral LD50 was stimated to be ~ 2500 mg/kg and dose-related anemia was found at all dose levels 14 days after dosing extramedullary hematopoiesis and hemosiderin deposition in the spleen. Based on these results, the read across was applied and the oral LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was determined to be 2317.10 mg/kg bw in rats.
Acute dermal toxicity: Read-across from experimental data on analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime:
Key study: An acute dermal toxicity test was perfomed in accordance with OECD 402 and GLP on analogue butan-2-one O,O',O''-(methylsilylidyne)trioxime in rats. No effects were observed and the dermal LD50 was determined to be >2000 mg/kg bw. Based on these results, the read-across was applied and the dermal LD50 for butan-2-one O,O',O'',O'''-silanetetrayltetraoxime was also determined to be >2000 mg/kg bw in rats.
Acute inhalation toxicity:
Data waingin (other justification): According to REACH Annex VIII, column 2: In addition to the oral route, for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route. The choice for the second route will depend on the nature of the substance and the likely route of human exposure. If there is only one route of exposure, information for only that route need be provided. This information is provided for dermal route.
Justification for selection of acute toxicity – oral endpoint
The study with highest reliability.
Justification for selection of acute toxicity – inhalation endpoint
According to REACH Annex VIII, column 2: In addition to the oral route, for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route. The choice for the second route will depend on the nature of the substance and the likely route of human exposure. If there is only one route of exposure, information for only that route need be provided. This information is provided for dermal route.
Justification for selection of acute toxicity – dermal endpoint
Only one study available.
Justification for classification or non-classification
Based on the available data on oral and dermal acute toxicity (LD50 > 2000 mg/kg bw), the butan-2-one O,O',O'',O'''-silanetetrayltetraoxime is not classified for acute toxicity according to CLP Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.